Daily Cosmetic Research Analysis
Analyzed 8 papers and selected 3 impactful papers.
Summary
Across today's selection, a large multicenter cohort suggests endovascular therapy retains meaningful benefit for anterior-circulation large ischemic stroke even in patients aged 80 and older. Urban waterways in Australia show widespread contamination with cosmetic-related synthetic musks, underscoring exposure pathways beyond wastewater. Real-world data over two years indicate sustained symptom and sexual function improvement after fractional CO-based energy therapy for genitourinary syndrome of menopause.
Research Themes
- Age-specific effectiveness of endovascular therapy in large-core ischemic stroke
- Environmental health impacts of cosmetic-related synthetic musks
- Real-world durability of energy-based therapies for GSM
Selected Articles
1. Impact of age on clinical outcomes after endovascular therapy for large ischemic stroke.
In a 38-center prospective registry subanalysis (N=745) of large-core anterior circulation stroke (ASPECTS ≤5), endovascular therapy improved 90-day functional outcomes versus standard care in patients ≤65 years (acOR 2.11) and ≥80 years (acOR 2.80), but not clearly in those 66–79 years. Functional gains diminished and mortality rose with age, yet age alone should not preclude EVT.
Impact: Clarifies age-stratified benefit of EVT in large-core stroke, directly informing selection criteria for older adults often excluded from trials.
Clinical Implications: Do not use chronological age alone to deny EVT in large-core anterior circulation stroke; incorporate individualized risk-benefit assessment, recognizing attenuated benefits and higher mortality with increasing age.
Key Findings
- EVT improved 90-day mRS distribution versus SMT in ≤65 years (acOR 2.11, 95% CI 1.16–3.81, P=0.01).
- EVT benefit persisted in ≥80 years (acOR 2.80, 95% CI 1.26–6.22, P=0.01).
- Predicted probability of mRS 0–3 decreased and mortality increased with advancing age in both EVT and SMT groups.
Methodological Strengths
- Prospective multicenter cohort with predefined outcomes and adjusted analyses
- Large sample size (N=745) spanning broad age spectrum
Limitations
- Non-randomized subanalysis with potential residual confounding
- Safety event rates (e.g., sICH) not detailed in the abstract
Future Directions: Randomized trials stratified by age and infarct core, with granular safety and quality-of-life endpoints; external validation across diverse health systems.
BACKGROUND: The impact of age on outcomes in patients with large ischemic stroke [defined as Alberta Stroke Program Early Computed Tomography Score (ASPECTS) ≤ 5] remains unclear. This study aimed to explore the effect of age on clinical outcomes after endovascular therapy (EVT) for acute anterior circulation large ischemic stroke. METHODS: This subanalysis enrolled patients with acute large ischemic stroke from a prospective multicenter cohort registry from 38 stroke centers across China between November 2021 and February 2023. Patients were stratified into the EVT and standard medical treatment (SMT) groups. The effectiveness outcomes included the distribution of modified Rankin Scale (mRS) score and functional outcomes (mRS 0-2, 0-3, and 0-4) at 90 days. Safety outcomes included 90-day mortality, symptomatic intracranial hemorrhage (ICH) within 48 h, and any ICH. RESULTS: A total of 745 eligible patients were included in the analysis. Compared with SMT, EVT showed improved 90-day outcomes across different age groups [aged ≤ 65 years, adjusted common odds ratio (acOR): 2.11, 95% confidence interval (CI) 1.16-3.81, P = 0.01; aged 66-79 years, acOR: 1.23, 95% CI 0.79-1.92, P = 0.36; aged ≥ 80 years, acOR: 2.80, 95% CI 1.26-6.22, P = 0.01], while the predicted probabilities of achieving mRS 0-3 decreased and mortality rate increased both in the EVT and SMT groups with advancing age (P CONCLUSIONS: In conclusion, age is a significant predictor of clinical outcomes in anterior circulation large ischemic stroke. While EVT benefits show progressive age-related decline, meaningful advantages persist even in patients aged ≥ 80 years, suggesting that age alone should not contraindicate EVT. However, further validation through large-scale randomized controlled trials is warranted.
2. Industrial, Residential, and Treated Effluents Contribute to Synthetic Musk Pollution in Australian Waterways.
In 20 urban waterway sites around Melbourne, passive samplers outperformed grab sampling, detecting eight synthetic musks at 70% of locations. Galaxolide concentrations reached up to 1550 ng/L; patterns suggested residential and wastewater influences, rural presence for some SMs, and higher musk ketone in industrial areas, indicating non-cosmetic sources.
Impact: Identifies widespread environmental presence and source patterns of cosmetic-related synthetic musks using robust passive sampling, informing exposure assessment and regulatory monitoring.
Clinical Implications: Clinicians should consider environmental fragrance exposures when evaluating dermatoses, respiratory sensitivities, or headache triggers; findings also support public health advocacy for monitoring and potential source control.
Key Findings
- Passive samplers (TRIMPS, Chemcatcher SDB-XC) detected eight synthetic musks versus four in grab samples.
- SMs were found at 70% of sites; galaxolide reached up to 1550 ng/L with highest frequency in wastewater- and residential-impacted areas.
- Musk ketone was highest in industrial areas, suggesting non-cosmetic sources; tonalide and galaxolide detected even at a rural site.
Methodological Strengths
- Comparison of passive versus grab sampling with GC-MS quantification
- Multi-site design linking concentrations to land-use patterns
Limitations
- No statistically significant land-use associations; limited temporal resolution
- Health risk assessment and human biomonitoring were not conducted
Future Directions: Longitudinal monitoring across seasons, integration with human biomonitoring, and source apportionment to guide regulatory actions.
Synthetic musks (SMs) are rarely included in routine monitoring programs and are typically investigated only in wastewater-impacted environments. There is limited understanding of their potential sources and transport from industrial and other urban areas. This study investigates the occurrence of SMs in urban waterways across the greater Melbourne area, Australia, by examining land-use associations. Sampling methods were also assessed by comparing grab water sample collection against trimethylpentane (TRIMPS) and Chemcatcher SDB-XC passive samplers. Surface water samples from 20 sites were extracted and analysed via solid-phase extraction and gas chromatography-mass spectrometry. Passive samplers detected a higher number of SMs (eight) compared to grab samples (four). Eight SMs-galaxolide, tonalide, cashmeran, celestolide, traseolide, phantolide, and musk ambrette and musk ketone-were detected in urban waterways, with SMs present at 70% of sites. No statistically significant land-use associations were found for SMs, yet distinct patterns emerged. Galaxolide reached the highest concentrations (up to 1550 ng/L) and detection frequency in wastewater- and residential- impacted areas. Tonalide and galaxolide were detected in rural site implying widespread use and possibly atmospheric transport. Cashmeran had a higher incidence of detection at residential sites, while musk ketone-internationally regulated in cosmetics-was highest in industrial areas, suggesting possible non-cosmetic sources. Polycyclic musks and nitro musks were present throughout the urban environment highlighting the need for continued monitoring and further research on their environmental distribution and impact.
3. Two-Year Real-World Outcomes in Women with Genitourinary Syndrome of Menopause Following Fractional CO
In a retrospective single-center cohort of 126 women with GSM undergoing a standardized three-session fractional CO-based therapy, all measured outcomes improved at 4–6 weeks with gains largely sustained at 1 year and still above baseline at 2 years. FSFI lubrication rose from 2.97±0.55 to 4.54±0.49 at 1 year; VSQ and FGSIS also showed persistent gains.
Impact: Provides two-year real-world durability data using validated patient-reported outcomes for an energy-based intervention in GSM, a field with ongoing evidence gaps and safety debates.
Clinical Implications: Energy-based fractional CO therapies may offer sustained symptom and sexual function improvements in GSM; clinicians should discuss potential benefits and uncertainties, and consider these options for patients not responding to standard care while awaiting higher-level evidence.
Key Findings
- All outcomes improved significantly at 4–6 weeks with p<0.0001, including GSM symptoms, sexual function, and genital self-image.
- Improvements were largely sustained at 1 year; scores at 2 years remained significantly better than baseline despite slight decline.
- FSFI lubrication improved from 2.97±0.55 at baseline to 4.54±0.49 at 1 year; VSQ and FGSIS showed persistent gains at 2 years.
Methodological Strengths
- Standardized three-session protocol with multiple validated PROMs (FSFI, VSQ, FGSIS)
- Multi-timepoint assessment out to two years
Limitations
- Retrospective, single-center design without a control group
- Potential selection and reporting biases; adverse events not detailed in the abstract
Future Directions: Conduct randomized, sham-controlled trials versus standard therapies (e.g., vaginal estrogen/moisturizers) with safety endpoints and durability beyond two years.
INTRODUCTION AND HYPOTHESIS: To evaluate the short- and long-term clinical outcomes of fractional CO METHODS: This retrospective single-center study included 126 postmenopausal women with GSM who underwent a standardized three-session fractional CO RESULTS: Significant improvement was observed in all outcome measures at 4-6 weeks, including GSM-related symptoms, sexual function, and genital self-image (all p < 0.0001). These benefits were largely sustained at 1 year. Although a slight decline was noted at 2 years, scores remained significantly improved compared to baseline. For example, FSFI lubrication scores improved from 2.97 ± 0.55 at baseline to 4.54 ± 0.49 at 1 year, and both VSQ and FGSIS demonstrated persistent gains at 2 years. Satisfaction scores continued to increase over time. Post hoc analyses confirmed significant differences across all evaluation time points. CONCLUSION: Fractional CO